No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
avelumab Sensitive: A1 - Approval
|
avelumab Sensitive: A1 - Approval
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
topotecan Sensitive: A2 - Guideline
|
topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
CAV Sensitive: A2 - Guideline
|
CAV Sensitive: A2 - Guideline
|
No biomarker
|
Merkel Cell Carcinoma
|
No biomarker
|
Merkel Cell Carcinoma
|
AST-008 Sensitive: B - Late Trials
|
AST-008 Sensitive: B - Late Trials
|
ARID2 mutation
|
Merkel Cell Carcinoma
|
ARID2 mutation
|
Merkel Cell Carcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
NTRK1 mutation
|
Merkel Cell Carcinoma
|
NTRK1 mutation
|
Merkel Cell Carcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Merkel Cell Carcinoma
|
PD-L1 expression
|
Merkel Cell Carcinoma
|
avelumab Sensitive: C3 – Early Trials
|
avelumab Sensitive: C3 – Early Trials
|
PD-1 expression
|
Merkel Cell Carcinoma
|
PD-1 expression
|
Merkel Cell Carcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
DLL3 expression
|
Merkel Cell Carcinoma
|
DLL3 expression
|
Merkel Cell Carcinoma
|
rovalpituzumab tesirine Sensitive: C4 – Case Studies
|
rovalpituzumab tesirine Sensitive: C4 – Case Studies
|
PD-L1 negative
|
Merkel Cell Carcinoma
|
PD-L1 negative
|
Merkel Cell Carcinoma
|
avelumab Sensitive: C4 – Case Studies
|
avelumab Sensitive: C4 – Case Studies
|
NCAM1 expression
|
Merkel Cell Carcinoma
|
NCAM1 expression
|
Merkel Cell Carcinoma
|
nivolumab Sensitive: C4 – Case Studies
|
nivolumab Sensitive: C4 – Case Studies
|
NKX2-1 expression
|
Merkel Cell Carcinoma
|
NKX2-1 expression
|
Merkel Cell Carcinoma
|
avelumab Sensitive: C4 – Case Studies
|
avelumab Sensitive: C4 – Case Studies
|